Urogen Pharma (NASDAQ:URGN) Receives $36.67 Average PT from Analysts

Urogen Pharma (NASDAQ:URGN) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $36.6667.

Several brokerages recently commented on URGN. D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a research report on Tuesday, March 31st. LADENBURG THALM/SH SH started coverage on shares of Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 price target for the company. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Urogen Pharma in a report on Monday. Finally, Oppenheimer upped their target price on Urogen Pharma from $34.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th.

Urogen Pharma Price Performance

Shares of NASDAQ:URGN opened at $29.88 on Friday. The business’s 50-day moving average is $22.51 and its 200 day moving average is $22.31. Urogen Pharma has a 1 year low of $3.61 and a 1 year high of $32.37. The firm has a market capitalization of $1.46 billion, a P/E ratio of -10.87 and a beta of 1.58.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million. On average, analysts expect that Urogen Pharma will post -0.98 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares during the last quarter. CWM LLC raised its position in Urogen Pharma by 18.0% during the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after buying an additional 650 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after acquiring an additional 1,653 shares during the period. Main Street Financial Solutions LLC lifted its stake in Urogen Pharma by 8.2% during the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock valued at $356,000 after acquiring an additional 1,968 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Urogen Pharma by 3.8% in the 4th quarter. Barclays PLC now owns 57,744 shares of the company’s stock valued at $1,352,000 after acquiring an additional 2,125 shares during the last quarter. 91.29% of the stock is owned by institutional investors and hedge funds.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.